person · Reporting owner

AHMED NADIM

Disclosed activity across 4 companies

Tapewire entity: 15727
SEC CIK: 0001731193

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BRISTOL MYERS SQUIBB COBMY · Entity 1662	EVP and President, Hematology	December 31, 2020	January 06, 2021
Cullinan Therapeutics, Inc.CGEM · Entity 4766	Director · President and CEO	February 24, 2026	February 25, 2026
Disc Medicine, Inc.IRON · Entity 2273	Director	June 18, 2026	June 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BRISTOL MYERS SQUIBB CO

Report date December 31, 2020 · Filed January 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	38,889	Ending reported balance After 2020-12-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2020-12-31 · Exercise / conversion · Acquired 14,946 · Balance 46,549 F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Row 2 · 2020-12-31 · Tax withholding · Disposed 7,660 · Balance 38,889 F2: Shares withheld for payment of taxes upon vesting of awards.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-31	Direct	0	Reported balance After 2020-12-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-12-31 · Exercise / conversion · Disposed 14,946 · Balance 0 F4: Each restricted stock unit converts into one share of common stock upon vesting. F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.
Common Stock, $0.10 par valueSEC Table I · non-derivative	Indirect401(k)	1,966	Reported balance Holding disclosure · report date 2020-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,966 F3: Based on recent 401(k) plan statement.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger, all outstanding Celgene Corporation (Celgene) Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

F2: Shares withheld for payment of taxes upon vesting of awards.

F3: Based on recent 401(k) plan statement.

F4: Each restricted stock unit converts into one share of common stock upon vesting.

Cullinan Therapeutics, Inc.

Report date February 24, 2026 · Filed February 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	390,803	Reported balance After 2026-02-24 transaction · row 1 1 source row Row 1 · 2026-02-24 · Sale · Disposed 13,515 · Balance 390,803 F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Disc Medicine, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.79 · Expires 2036-06-17	Direct	5,176	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 5,176 · Balance 5,176 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.18 · Expires 2027-01-30	Direct	Reported balance After 2019-11-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 6,563 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $124.06 · Expires 2027-05-01	Direct	Reported balance After 2019-11-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.41 · Expires 2027-07-31	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 3,125 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.97 · Expires 2027-10-30	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.26 · Expires 2028-01-29	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.13 · Expires 2028-05-08	Direct	Reported balance After 2019-11-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30	Direct	Reported balance After 2019-11-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-20 · Disposition to issuer · Disposed 10,548 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.43 · Expires 2028-10-29	Direct	Reported balance After 2019-11-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-11-20 · Disposition to issuer · Disposed 10,549 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-11-20 · Disposition to issuer · Disposed 1,563 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-11-20 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-11-20 · Disposition to issuer · Disposed 5,357 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-11-20 · Disposition to issuer · Disposed 3,348 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This option was fully exercisable.

F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	6,975	$0.00 Strike: $55.44	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 14 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock, $0.10 par value · 6,975 shares Expires 2024-10-27 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	13,949	$0.00 Strike: $47.12	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 13 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,949 Underlying: Common Stock, $0.10 par value · 13,949 shares Expires 2024-07-28 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	6,974	$0.00 Strike: $39.95	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 12 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,974 Underlying: Common Stock, $0.10 par value · 6,974 shares Expires 2024-02-03 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	7,440	$0.00 Strike: $43.85	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 11 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,440 Underlying: Common Stock, $0.10 par value · 7,440 shares Expires 2023-12-02 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	6,975	$0.00 Strike: $42.00	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 10 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock, $0.10 par value · 6,975 shares Expires 2023-10-28 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	6,975	$0.00 Strike: $38.35	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 9 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,975 Underlying: Common Stock, $0.10 par value · 6,975 shares Expires 2023-07-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	6,974	$0.00 Strike: $31.85	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 8 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,974 Underlying: Common Stock, $0.10 par value · 6,974 shares Expires 2023-04-29 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	10,463	$0.00 Strike: $26.60	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 7 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,463 Underlying: Common Stock, $0.10 par value · 10,463 shares Expires 2023-01-28 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	16,740	$0.00 Strike: $21.63	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 6 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,740 Underlying: Common Stock, $0.10 par value · 16,740 shares Expires 2022-12-17 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	10,464	$0.00 Strike: $19.72	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 5 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 Underlying: Common Stock, $0.10 par value · 10,464 shares Expires 2022-10-31 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	10,460	$0.00 Strike: $19.61	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,460 Underlying: Common Stock, $0.10 par value · 10,460 shares Expires 2022-04-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantOption (right to buy) · Derivative	3,255	$0.00 Strike: $19.55	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · derivative · entry 3 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,255 Underlying: Common Stock, $0.10 par value · 3,255 shares Expires 2022-01-30 F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	1,966	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Disclosed balance after: 1,966 F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantCommon Stock, $0.10 par value	14,819	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000212 · wf-form4_157489385725608.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,819 F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person. F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	33,182	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 6 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,182 Underlying: Common Stock, $0.10 par value · 33,182 shares Expires 2022-03-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F9 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F9 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	51,614	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 5 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,614 Underlying: Common Stock, $0.10 par value · 51,614 shares Expires 2022-03-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	6,228	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,228 Underlying: Common Stock, $0.10 par value · 6,228 shares Expires 2022-02-04 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on February 4, 2020. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on February 4, 2020. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	9,965	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 3 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,965 Underlying: Common Stock, $0.10 par value · 9,965 shares Expires 2021-05-08 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on May 8, 2019. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on May 8, 2019. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	14,945	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,945 Underlying: Common Stock, $0.10 par value · 14,945 shares Expires 2021-03-01 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F5 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award. F5 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Nov 27, 2019 22:31 UTC	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	4,650	$0.00	$0.00	Disclosure SEC source: 0000014272-19-000213 · wf-form4_157489387998406.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Common Stock, $0.10 par value · 4,650 shares Expires 2020-10-30 F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018. F3 · date: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person. F1 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on October 30, 2018. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:37 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	33,183	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000034 · wf-form4a_157810181956331.xml · derivative · entry 2 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,183 Underlying: Common Stock, $0.10 par value · 33,183 shares Expires 2021-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
November 20, 2019 Filed Jan 4, 2020 01:37 UTC Amendment	BRISTOL MYERS SQUIBB CO BMY · Entity 1662	GrantRestricted Stock Units · Derivative	14,946	$0.00	$0.00	Disclosure SEC source: 0000014272-20-000034 · wf-form4a_157810181956331.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · President, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,946 Underlying: Common Stock, $0.10 par value · 14,946 shares Expires 2020-12-31 F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards. F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. F5 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee. F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award. F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting. F4 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	3,281	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001255 · form4-11042019_041106.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	1,096	$108.03	$118,400.88	Disclosure SEC source: 0001415889-19-001255 · form4-11042019_041106.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,819 Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	3,281	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001255 · form4-11042019_041106.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., GLOBAL HEM. AND ONC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	1,563	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000506 · form4-05062019_040506.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	490	$95.21	$46,652.90	Disclosure SEC source: 0001415889-19-000506 · form4-05062019_040506.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,634 Read SEC document
May 02, 2019 Filed May 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	1,563	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000506 · form4-05062019_040506.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
March 01, 2019 Filed Mar 5, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	27,749	$0.00	$0.00	Disclosure SEC source: 0001415889-19-000248 · form4-03052019_040307.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,749 Underlying: Common Stock · 27,749 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
February 04, 2019 Filed Feb 6, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantRestricted Stock Unit · Derivative	3,348	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-19-000135 · form4-02062019_040210.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,348 Underlying: Common Stock · 3,348 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:26 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001770 · form4-12182018_031217.xml · derivative · entry 4 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:26 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Tax withholdingCommon Stock	1,477	$68.20	$100,731.40	Disclosure SEC source: 0001415889-18-001770 · form4-12182018_031217.xml · nonDerivative · entry 2 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,561 Read SEC document
December 16, 2018 Filed Dec 18, 2018 18:26 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001415889-18-001770 · form4-12182018_031217.xml · nonDerivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,038 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
October 29, 2018 Filed Oct 31, 2018 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	10,549	$0.00 Strike: $71.43	$0.00	Disclosure SEC source: 0001415889-18-001567 · form4-10312018_041001.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,549 Underlying: Common Stock · 10,549 shares Expires 2028-10-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option will vest in four equal annual installments commencing on October 29, 2019. Read SEC document
July 30, 2018 Filed Aug 1, 2018 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantStock Option (right to buy) · Derivative	10,548	$0.00 Strike: $88.91	$0.00	Disclosure SEC source: 0001415889-18-001204 · form4-08012018_040820.xml · derivative · entry 1 AHMED NADIM · CIK 0001731193 · PRES., HEMATOLOGY AND ONCOLOGY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,548 Underlying: Common Stock · 10,548 shares Expires 2028-07-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.